IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, single arm, prospective, open-label phase II trial investigating the
clinical activity of peri-interventional treatment with the anti-PD1 antibody pembrolizumab
in HCC patients who are candidates for local ablation via either radiofrequency ablation
(RFA) or microwave ablation (MWA) or brachytherapy or combination of TACE with RFA, MWA or
brachytherapy.
Phase:
Phase 2
Details
Lead Sponsor:
IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest